about
Main roads to melanomaDiscrepant alterations in main candidate genes among multiple primary melanomasRegulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatmentRan signaling in melanoma: implications for the development of alternative therapeutic strategies.Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy.Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.NEMO-binding domain peptide inhibits proliferation of human melanoma cells.Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.Analysis of T and NK cells immune response in Ipilimumab treated Melanoma patients.Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup studyBaseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumabPD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumabProteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutationsAutomatic discovery of image-based signatures for ipilimumab response prediction in malignant melanomaFrequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patientsErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine NeuregulinEnzyme activity of circulating CD73 in human serumAccumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway
P50
Q21245465-E61EEFAA-6602-45F3-B8C1-CCB17C5B9836Q30578299-2B303755-6A72-4E0B-B12C-3829DFC38E22Q34114136-B7286701-5113-4864-8493-075320A81545Q34778951-44A1A3D5-878A-4E70-A340-F4D379DE5DAAQ35033377-40B1F400-1D70-4B5D-8FE3-9898C219F3F3Q35798996-EC157EFD-8E86-43ED-8F8F-274574F4C006Q37029158-668AD221-2DB1-40A1-9BBA-861B3EB83BCDQ37152975-4CA69C79-8160-4200-8B38-FED3399625B3Q37267893-EAE34601-9619-45FA-B40C-252ACDC2AC64Q39572754-0AD89E8C-683B-4167-AADF-326A81B0B975Q39917777-8FD0F8B8-DEE0-478C-916F-B19D752A1738Q40226135-97E292BC-8F5B-4CA1-BAD1-4F26C9B4AA7EQ40355238-0101DB7F-7E8A-46AC-B4A7-39EEB16443B8Q40758666-2F4932F6-CFDC-4F13-B2DD-A7A139F6F650Q43215888-F43AE819-FE27-4AAC-886A-B81B6319B3C0Q45765887-C00D8815-7287-4E8D-8626-7798F122ECC0Q47131425-30FC79B1-23EF-4D68-8DA6-AE16FDD9680FQ48499411-C578DC0A-7C2F-4489-97E4-E1DB8CBBBFCBQ52659362-658EE009-91FB-4338-B41A-C0653E331E1AQ55673215-0295A86B-DFDA-4942-96D7-BEA8B13CD599Q57475128-E0930E64-2061-46E5-8110-D2BFC481376AQ62661800-19BDC6B7-8738-43E3-8148-C7516EB36C22Q62661814-A17D59F2-010E-4FAC-B8C8-C999316FF7CEQ64103569-9CC521F7-8027-41A1-8C79-E90419B76CCAQ64259329-FA0E75E9-9D5A-45CF-A8C3-2A240B58D6FCQ90242301-82634539-663B-4C37-910A-8E954BB0BC3CQ90310892-1B382099-370E-4FA1-9CDC-818E2BF1911BQ91284470-26F9AB5F-F724-40B9-9848-F6A6A83657F0Q92800600-4B50E432-F80F-443A-BA43-1DC3C1D566EA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mariaelena Capone
@ast
Mariaelena Capone
@en
Mariaelena Capone
@es
Mariaelena Capone
@fr
Mariaelena Capone
@nl
Mariaelena Capone
@sl
type
label
Mariaelena Capone
@ast
Mariaelena Capone
@en
Mariaelena Capone
@es
Mariaelena Capone
@fr
Mariaelena Capone
@nl
Mariaelena Capone
@sl
prefLabel
Mariaelena Capone
@ast
Mariaelena Capone
@en
Mariaelena Capone
@es
Mariaelena Capone
@fr
Mariaelena Capone
@nl
Mariaelena Capone
@sl
P1053
J-8670-2016
P106
P1153
25635111500
P21
P31
P3829
P496
0000-0002-1352-2532